{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001695","form_type":"8-K","ticker":"AGPU","cik":"0001446159","company_name":"Axe Compute Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.216025+00:00","generated_at":"2026-06-04T06:00:04.849125+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Predictive Oncology FY2023 revenue $1.78M, net loss $14M, EPS -$3.48","bullets":["Net loss of ~$14M on total revenue of ~$1.8M for year ended Dec 31, 2023.","Basic and diluted EPS improved 50% YoY to -$3.48 from -$6.98.","Cash and cash equivalents $8.7M at Dec 31, 2023, down from $22.1M at Dec 31, 2022.","Collaboration progress: FluGen intranasal flu vaccine, Cancer Research Horizons glutaminase inhibitors, UPMC ovarian cancer AI study.","Q4 net loss per share $0.74; company cited cash burn of $13.2M in operating activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001695","json":"https://secwatch.observer/filing/0001171843-24-001695.json","markdown":"https://secwatch.observer/filing/0001171843-24-001695.md","text":"https://secwatch.observer/filing/0001171843-24-001695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446159/000117184324001695/0001171843-24-001695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446159/000117184324001695/f8k_032824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:00:04.849125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f59044b0b0d79321fabb1bb2675cdda97ef62a5","claim":"Axe Compute Inc. reported the year ended December 31, 2023 results: revenue approximately $1.8 million, net income approximately $14 million, EPS $3.48 per share.","evidence_excerpt":"results for the year ended December 31, 2023, and provided a corporate update. The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023. Q4 2023 and Recent Highlights: Reported meaningful progress with FluGen collaboration designed to bring a first-of-its-kind intranasal flu","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446159/000117184324001695/0001171843-24-001695-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"approximately $1.8 million"},{"label":"Net income","value":"approximately $14 million"},{"label":"EPS","value":"$3.48 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}